Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Companies / News/  Emcure to buy global rights of chemotherapy brand
BackBack

Emcure to buy global rights of chemotherapy brand

Emcure to sell the product through its subsidiaries and its marketing and distribution partners

The acquisition is expected to increase Emcure’s presence in the global oncology market and serve as an anchor product in building the company’s oncology franchise. (The acquisition is expected to increase Emcure’s presence in the global oncology market and serve as an anchor product in building the company’s oncology franchise.)Premium
The acquisition is expected to increase Emcure’s presence in the global oncology market and serve as an anchor product in building the company’s oncology franchise.
(The acquisition is expected to increase Emcure’s presence in the global oncology market and serve as an anchor product in building the company’s oncology franchise.)

Mumbai: Emcure Pharmaceuticals Ltd is to acquire worldwide rights for Bristol-Myers Squibb Co.’s BiCNU injection, a chemotherapy agent indicated for treatment of brain tumours, multiple myeloma and a few other types of cancers, for an undisclosed sum.

Under the agreement, Pune-based Emcure will acquire the marketing rights and authorizations, trademarks, technology and the know-how related to the product following a transition period during which US-based Bristol-Myers will continue to distribute the product.

Emcure plans to sell the product through its subsidiaries, including Heritage Pharmaceuticals Inc. in the US, and in some cases through Emcure’s marketing and distribution partners in other markets.

“The acquisition of BiCNU demonstrates Emcure’s commitment to building a leading franchise in the global oncology market," Emcure chief executive officer Satish Mehta said on Tuesday.

The acquisition is expected to increase Emcure’s presence in the global oncology market and serve as an anchor product in building the company’s oncology franchise.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 08 Jan 2013, 05:54 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App